⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464607 | 0.81 | — | — | |
| SCHEMBL302004 | 0.71 | — | — | |
| SCHEMBL3466239 | 0.67 | — | — | |
| SCHEMBL15271444 | 0.67 | — | — | |
| SCHEMBL6167812 | 0.65 | — | — | |
| SCHEMBL17242630 | 0.63 | — | — | |
| Water SCHEMBL9832507 | 0.60 | — | — | |
| SCHEMBL975833 | 0.57 | — | — | |
| SCHEMBL4872377 | 0.55 | DYRK1A (0.32) | — | |
| SCHEMBL1612976 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | claimed |
| EP-3259270-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | Incyte Corporation (US) | 2017-12-27 | — | — | EP | claimed |
| WO-2016134314-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION (US) | 2016-08-25 | — | — | WO | claimed |
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | claimed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| US-20200399267-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-20190241560-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20180244672-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2018-08-30 | — | — | US | disclosed |
| US-9890156-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3259270-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | Incyte Corporation (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016134314-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20140128452-A1 | SUGAR CHAIN-RELATED GENE AND USE THEREOF | STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-8071651-B2 | 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-1948654-B1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| EP-1948654-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007031558-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | WO | disclosed |